GLP1R and type 2 diabetes mellitus: Noteworthy, monotherapy with compound 15, or in combination with either liraglutide (GLP-1R agonist) or empagliflozin (SGLT2 inhibitor), elicited greater beneficial effects on both fasting glucose levels and glucose tolerance than either liraglutide or empagliflozin alone, suggesting compound 15 could represent an improvement on existing therapies for type 2 diabetes.